H-GADGVGKSA-OH

Ref. 3D-PP43987

Produktinformation

• Name: H-GADGVGKSA-OH
• Synonyme: NH2-Gly-Ala-Asp-Gly-Val-Gly-Lys-Ser-Ala-OH

Beschreibung

Peptide H-GADGVGKSA-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-GADGVGKSA-OH include the following: Diverse neoantigens and the development of cancer therapies RM Srivastava , TA Purohit , TA Chan - Seminars in radiation oncology, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1053429619300761 Neoantigen T-cell receptor gene therapy in pancreatic cancer R Leidner , N Sanjuan Silva, H Huang - England Journal of , 2022 - Mass Medical Sochttps://www.nejm.org/doi/full/10.1056/NEJMoa2119662 Mutated RAS: targeting the"Untargetable" with T cells PD Chatani, JC Yang - Clinical Cancer Research, 2020 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/26/3/537/83143 Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy P Bai, Y Li, Q Zhou, J Xia, PC Wei , H Deng - , 2021 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2020.1868130 Characters of neoantigens in cancer immunotherapy P Bai, Y Li, Q Zhou, J Xia, M Wu, H Deng, JW Kappler - bioRxiv, 2019 - researchgate.nethttps://www.researchgate.net/profile/Philippa-Marrack/publication/334462311_Characters_of_neoantigens_in_cancer_immunotherapy/links/5f80a085a6fdccfd7b5520a6/Characters-of-neoantigens-in-cancer-immunotherapy.pdf Rational discovery of a cancer neoepitope harboring the KRAS G12D driver mutation P Bai, Q Zhou, P Wei , H Bai, SK Chan - Science China Life , 2021 - Springerhttps://link.springer.com/article/10.1007/s11427-020-1888-1 High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D MJW Sim , J Lu, M Spencer , F Hopkins - Proceedings of the , 2020 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1921964117 Immunogenicity and immune silence in human cancer M Yarmarkovich , A Farrel, A Sison III - Frontiers in , 2020 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2020.00069/full MediMer: a versatile do-it-yourself peptide-receptive MHC class I multimer platform for tumor neoantigen-specific T cell detection M Meyer, C Parpoulas, T Barthelemy - Frontiers in , 2024 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2023.1294565/full Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens AY Parikh, R Masi, B Gasmi , K Hanada - Cancer Immunology , 2023 - Springerhttps://link.springer.com/article/10.1007/s00262-023-03476-6

• Marke: Biosynth